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Alterations in brain metal ion homeostasis have been reported with aging and are
implicated in the pathogenesis of neurodegenerative diseases. To assess whether
age-related changes in hypothalamic-pituitary-gonadal (HPG) hormones might be
involved in modulating brain metal ion homeostasis, we treated 7.5-month intact,
sham-ovariecomized and ovariectomized C57B6SJL mice with vehicle or leuprolide
acetate (for 9-months) to differentiate between whether sex steroids or gonadotropins
might modulate brain metal ion concentrations. Unlike other aging mammals, there was
no increase in plasma luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
concentrations following estropause in mice, suggesting there was sufficient residual
production by the follicle depleted ovary, of sex steroids like estrogens and protein
hormones like the inhibins, in order to suppress pituitary LH/FSH production. Castration
on the other hand induced significant increases in circulating LH and FSH. Modulation of
plasma sex steroid and gonadotropin levels did not significantly alter the concentrations
of brain metals tested (Fe, Zn, Cu, Mn, Co, Ni, Al, Li), although there was a tendency for a
decrease in all brain metals following ovariectomy (low estrogens and progesterone, high
gonadotropins), a response that was reversed with leuprolide acetate treatment (low sex
steroids, low gonadotropins). Brain Cu concentration was the only metal correlated with
plasma LH (−0.37, n = 30, p < 0.05) and FSH (−0.42, n = 29, p < 0.01). This study
demonstrates that sex hormones do not markedly alter brain metal ion homeostasis,
unlike previously reported studies of circulating metal ion homeostasis. The role of
gonadotropins in regulating metal ion homeostasis does however warrant further study.
Keywords: metals, brain, sex hormones, AbetaPP transgenic mouse, leuprolide acetate, ovariectomy, copper

INTRODUCTION
Metal ion homeostasis is largely unaltered in mice of reproductive age [e.g., (1)]. However, studies
in mice and humans show that the concentrations of Fe, Cu and Co increase in several tissues
including the brain during normal aging (1–7), while the concentration of brain Mn decreases (1)
and the concentration of Zn either remains unchanged or shows a slight decrease (1, 4, 6, 8, 9).
These results imply an age-related change in the homeostatic mechanisms regulating brain metal
ion concentrations.
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Metal ions also have been postulated to play a role in
the pathogenesis of age-related neurological disorders such
as Alzheimer’s disease [AD; (10, 11)]. Cu, Zn, and Fe are
concentrated in and around amyloid plaques in the AD brain
(12), and high levels of Zn (13) and Fe (14) have been
reported in the amyloid plaques of the Tg2576 mouse model
of AD. Numerous reports also have demonstrated transition
metal imbalances in the parenchyma of the AD brain, such
as decreased Cu, and increased Fe, Zn, Mn (15–20) and Al
[e.g., (21)].
Aging is associated with marked changes in hormones
of the hypothalamic-pituitary-gonadal (HPG) axis, which are
implicated in the etiology of AD (22, 23). These changes
include the loss of gonadal sex steroid and inhibin production,
and marked elevations in hypothalamic gonadotropin-releasing
hormone (GnRH) secretion (24) and serum (25–27) and CSF
gonadotropin levels (28). The more abrupt changes in HPG
axis hormones in women at menopause compared with men
during andropause has been proposed as an explanation for the
increased prevalence of AD in women compared with men [∼2:1
ratio; (23)].
Evidence supporting hormonally-induced changes in metal
ion homeostasis come from early studies demonstrating that
Cu (but not Zn) is positively correlated with plasma estrogen
and progesterone during the estrous cycle, after ovariectomy
and during administration of these sex steroids to female
Sprague-Dawley rats (29). An impact of circulating metals on
brain metal homeostasis is suggested by 1) increases in Zn
concentrations in the brain (minus cerebellum) and cerebellum,
and increased Cu in the cerebellum, after both estrone and
testosterone treatment of mice (30) and 2) significant decreases
in immunohistochemically detectable Fe in the cerebral cortex
during diestrus (low estradiol) compared to proestrus when
estradiol levels are highest (31). In this latter study, there was a
shift in Fe localization from neurons to vascular endothelial cells
and oligodendrocytes in the transition from diestrus to proestrus.
Additional evidence supporting a role for sex hormones in
modulating brain metals is indicated by gender differences in Zn
levels in the brains of aging mice (1) and lower Cu and Mn levels
in the brains of female mice compared to male mice at any age
(32). The total amount of Fe present in the serum, liver and the
substantia nigra also fluctuates during the estrous cycle in female
rats (33), as does hypothalamic Zn and Cu that rise between
proestrus and estrus and fall again at diestrus (34). These workers
also demonstrated that castration decreased the concentrations
of Fe, Cu and As in both pituitary and hypothalamus, while
zinc concentrations rose. Male rats also had lower pituitary
concentrations of Fe, Cu, Zn, As, and Rb than cycling females.
Together these data raise the possibility that changes in the
concentration of circulating HPG hormones can influence the
intercellular transport of metals in the brain. We therefore
undertook this study to assess which HPG hormones might
be involved in modulating brain metal ion homeostasis. We
modulated serum hormone levels with both ovariectomy and
leuprolide acetate, both alone and in combination to differentiate
between whether sex steroids or gonadotropins might modulate
brain metal ion concentrations. Modulation of plasma sex
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steroid and gonadotropin levels did not alter any brain metals
tested, although there was a tendency for a decrease in brain
Cu following ovariectomy (low estrogens, high gonadotropins)
which was reversed with leuprolide acetate treatment (low
sex steroids, low gonadotropins) of these mice. Our results
indicate the importance of metal ion homeostasis for normal
brain function.

METHODS
Animals
Female C57B6SJL mice (Taconic, Germantown, NY) were housed
under a 12-h light, 12-h dark cycle, with food and water available
ad libitum. All procedures performed on animals were reviewed
and approved by the Animal Resource Center of Case Western
Reserve University before the initiation of the study.

Experimental Design
Due to the short half-life and expense of luteinizing hormone
(LH) and follicle-stimulating hormone (FSH), administration
of these gonadotropins via injection or pumps is not feasible
for long-term studies. We therefore used ovariectomy to
induce elevated levels of blood LH and FSH, a procedure
that mimics the abrupt loss of estrogen following menopause.
Conversely, leuprolide acetate (leuprolide) was administered
intramuscularly to lower blood gonadotropin levels. Leuprolide
is a synthetic analog of gonadotropin-releasing hormone (GnRH)
acting mainly on the pituitary gland. Continuous treatment
produces initial stimulation of the pituitary and an increase
in blood gonadotropins, followed by a suppression of blood
gonadotropins and sex steroids to castrate/post-menopausal
levels within ∼ 1 week due to suppression of GnRH receptor.
In females, both ovarian estrogen and androgen synthesis
are inhibited.
In this study, female C57B6SJL mice at ∼7.5 months of
age (prior to amyloid deposition in the Tg2576 mice) were
allocated to 5 different groups: either left intact and treated with
vehicle, intact and treated with leuprolide, sham-ovariectomized,
ovariectomized or ovariectomized and treated with leuprolide
for 9 months (until ∼16.5 months of age). Table 1 summarizes
the experimental design and predicted effects of each treatment
on blood hormone levels. In the ovariectomized vehicle group,
blood LH and FSH level will be high but estrogen levels low;
in the ovariectomized leuprolide-treated group, blood LH, FSH
and estrogen level will be low. This experimental design allows
differentiation between the effects of gonadotropins and sex
steroids on brain metals.

Treatments
Leuprolide acetate (Lupron Depot, TAP Pharmaceuticals Inc.,
Lake Forest) is a GnRH agonist that lowers LH/FSH levels by
desensitizing GnRH receptor signaling that subsequently leads
to decreased LH/FSH secretion and decreased blood sex steroid
levels. Leuprolide is mixed with a diluent in a prefilled dualchamber syringe containing sterile lyophilized microspheres, to
form a suspension. Leuprolide is gradually released from the
microspheres after injection over a 4-week period. Animals were
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TABLE 1 | Summary of treatment groups for hormonal modulation of sex steroids and gonadotropins.
Group name

LH and FSH level c.f. control

Estrogen level c.f. control

Number of mice

Age at euthanasia (month)

Control -Vehicle

Normal

Normal

6

16

Leuprolide

Low

Low

6

16

Sham OVX

Normal

Normal

6

16

Sham OVX + Vehicle

High

Low

6

16

OVX + Leuprolide

Normal

Low

6

16

in a water bath until the solution was clear. After cooling
to room temperature, ∼150 µL of 30% H2 O2 , was added
and after the effervescence ceased, the samples were incubated
at 70◦ C for 15 min. and then cooled to room temperature.
The final volume was brought to 5 mL with 1% metal grade
nitric acid. Samples were then analyzed for Fe, Zn, Cu, Mn,
Co, Ni, Al and Li using inductively coupled plasma-mass
spectrometry (ICP-MS) at the Soil & Plant Analysis Laboratory,
University of Wisconsin-Madison. The metal ion contents of
the buffer solutions were subtracted from the samples. VG
PlasmaQuad PQ2 Turbo Plus ICP-MS was the apparatus used.
Samples in solution were converted to aerosols via a nebulizer,
and the aerosols are transported to the inductively coupled
plasma, a high temperature zone (8,000–10,000◦ C). The analytes
were heated (excited) to the respective ions. In a quadrupole
mass filter, ions are separated based on their mass-to charge
and the ion intensities at different masses were measured
(mass spectrometry). Ion intensities are proportional to the
respective concentrations of analytes in the aqueous sample. The
quantification was an external multi-point linear calibration by
comparing the ion intensity of an unknown sample with that of
a standard sample. Multielement calibration standard solutions
were prepared from single- and multielement primary and/or inhouse working standard solutions. Rhodium (Rh) was used as an
internal reference standard. Containers (bottles, vials, etc) were
soaked in 10% nitric acid overnight and rinsed with de-ionized
water several times before use.

injected with vehicle or leuprolide acetate (1.5 mg/kg) biweekly
during the first month and monthly thereafter for 9 months.
Mice were ovariectomized using a bilateral dorsal approach at
29 weeks of age. After the wounds healed 1 week later, mice
were injected with either vehicle (saline) or leuprolide acetate
(1.5 mg/kg). Animals were weighed monthly after saline or
leuprolide injection.

Tissue Collection
Blood was collected at the commencement of the experiment (∼7
months of age) and at the end of the 1st and 3rd month from an
orbital sinus after mice were anesthetized with an IP injection of
mouse anesthesia cocktail (0.1 mL/25 g containing ketamine HC1
15 mg (100 mg/mL) 0.15 mL; xylazine HC1 3 mg (20 mg/mL)
0.15 mL; acepromazine 0.5 mg (10 mg/mL) 0.05 mL; and sterile
saline 1.4 mL). The final bleed at 9 months was collected by
heart puncture (see below). Blood was collected from animals
prior to their next dose of leuprolide. Blood (100–400 µL)
was collected into EDTA-coated tubes which were centrifuged
at 1,000 g for 3 min. at 4◦ C, followed by centrifugation at
5,000 g for 10 min. prior to the collection of plasma which was
stored -80◦ C.
Mice were sacrificed at 16 months of age with an
injection of sodium barbital (392 mg/mL, 50 µL each, IP).
Blood was collected at this time by heart puncture, and
the animals were then perfused with phosphate buffered
saline (0.01 M, pH 7.4, Gibco, Invitrogen, Carlsbad, CA) and
decapitated. The brain was removed from the skull and one
hemisphere frozen in liquid nitrogen and stored at −80◦ C for
metal ion analyses.

Statistical Analyses
Two-way ANOVA with repeated measures of one factor was used
to assess statistically significant differences between treatment
groups and temporal changes for plasma hormones and animal
weights. Tukey’s post-hoc tests were carried out to compare
specific groups using the GraphPad Prism Software Version
5.0 (San Diego, CA). t-test and one-way ANOVA were used
to analyze statistically significant differences between treatment
groups for brain metals. Experiments on the vehicle and
leuprolide treated group were performed at a different time
to the sham operated, ovariectomized, and ovariectomized and
leuprolide treated groups due to the availability of animals. To
avoid potential systemic errors between these two subgroups,
we performed separate statistical analyses. A correlation matrix
of the endpoints (plasma hormones, body weight and brain
metals) measured in this study was performed using Statview v5,
SAS Institute.

Hormone Assays
The levels of LH and FSH were assayed by radioimmunoassay at
the National Hormone and Peptide Program (Torrance, CA).

Metal Ion Analysis
A brain hemisphere without the cerebellum and olfactory
bulb was weighed and then homogenized in Tris buffer, pH
7.6 (20 mM; ultra pure Tris; MP Biomedicals, Aurora, OH)
containing EDTA (1 mM), EGTA (1 mM) and a protease
inhibitor cocktail (all from Sigma, St. Louis, MO). Following
protein analysis by using the BCA assay (Pierce, Rockford, IL),
approximately one third of the homogenate (∼150 µL) was
prepared for metal analysis as previously reported (1). Briefly,
samples were mixed with 150 µL of 70% metal grade nitric
acid (Fisher Scientific, Pittsburgh, PA) and incubated at 80◦ C
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RESULTS

LH, this increase in plasma FSH is consistent with a loss of
negative feedback by 17β-estradiol on the hypothalamus with
the decline in reproductive function in female mice at this time
(37). Leuprolide acetate treatment significantly suppressed the
concentration of FSH in plasma at 3 (5.86 ± 1.03 vs. 11.14 ±
1.88; P = 0.05; n = 8–9) and 9 (6.7 ± 0.69 vs. 10.3 ± 1.98; P
= 0.05; n = 8) months post-treatment, but not at 1 (5.20 ± 1.16
vs. 3.33 ± 1.33; P = 0.05; n = 5) or 6 (9.00 ± 1.34 vs. 9.00 ±
1.92; P = 0.05; n = 5–6) months post-treatment (Figure 2B).
In sham ovariectomy mice, there was an initial significant 3fold increase in plasma FSH at 1 month (14.5 ± 3.71 P < 0.05;
n = 6) and the concentration of FSH remained at this level
to 9 months post-surgery (11.24 ± 2.58; n = 6). Ovariectomy
induced a significant 17.1-fold increase in the concentration of
plasma FSH from 4.36 ± 0.66 pre-surgery to 74.5 ± 5.60 (P <
0.05; n = 6) at 1 month post-surgery and the concentration of
plasma FSH remained at this level to 9 months post-surgery.
Leuprolide acetate treatment of mice that were ovariectomized
partially suppressed the surge in plasma FSH at 1 month (29.83
± 5.67; n = 6) and 3 month (33.69 ± 3.01; n = 6) and completely
suppressed plasma FSH concentrations to sham ovariectomy
levels by 9 months post-surgery (14.37 ± 2.02; n = 6).
Overall, these results indicate that leuprolide acetate
suppresses plasma LH and FSH in aging mice, and that the
ovariectomy induced surge in plasma LH and FSH is suppressed
by leuprolide acetate.

Mouse Weights
The weights of control animals and leuprolide treated animals
progressively increased 37% and 45 %, respectively, from 7.5
months of age (0 months post-treatment) to 15.5 months
(8 months post-treatment) of age (Figure 1A). No significant
difference in mouse weights was found between vehicle
and leuprolide treated groups, but time was found to be
a factor that influenced weights significantly. Control mice
reached significantly heavier weights earlier (12.5 months) than
leuprolide treated mice (14.5 months).
The weights of sham-operated, ovariectomized and
ovariectomized plus leuprolide treated animals progressively
increased 33, 33, and 32%, respectively, from 7 months (0 months
post-treatment) to 15 months (8 months post-treatment) of
age (Figure 1B). There was no significant difference in weights
among sham operated, ovariectomized and ovariectomized
and leuprolide treated groups, but time was found to be a
factor that influenced weights significantly. Ovariectomized and
ovariectomized plus leuprolide treated mice reached significantly
heavier weights earlier (9 months) than sham-operated mice
(11 months).

Plasma Hormones
To confirm that ovariectomy and leuprolide acetate treatments
modulated blood hormone levels, plasma collected from mice
at 0, 1, 3, and 9 months (and also 6 months for vehicle and
leuprolide treated groups) post-treatment were analyzed for LH
and FSH concentrations (Figures 2A,B; respectively). There was
a gradual 38% increase in the concentration of plasma LH from
0.47 ± 0.085 at 7.5 months of age (time 0 months) to 0.75 ± 0.09
(mean ± SEM; P < 0.05; n = 6) at 16.5 months of age (time 9
months). This increase in plasma LH, albeit non-significant, is
consistent with the loss of negative feedback by 17 β-estradiol on
the hypothalamus with the decline in reproductive function in
female mice at this time (35, 36). The concentration of plasma
LH in the leuprolide acetate treated mice was the same as vehicle
treated mice at time 0, and remained at this lower concentration
with the difference from the vehicle treated group becoming
significant at the 6 month time point (Figure 2A).
The concentration of plasma LH did not change between 7 and
16 months of age in sham ovariectomized animals (Figure 2A).
Ovariectomy induced a significant and progressive increase in
the concentration of plasma LH such that by 9 months postsurgery (16 months of age), plasma LH concentrations were 8.6fold elevated compared to time 0 (7 months of age; 5.7 ± 1.1 vs.
0.66 ± 0.16, respectively; P < 0.05; n = 6). Leuprolide acetate
treatment of ovariectomized mice suppressed the surge in the
concentration of plasma LH, and suppression was not obvious
at 1 month post-treatment, but became significant at 3 months
post-treatment and more so at 9 months post-treatment where
the concentration of plasma LH was reduced to the same level as
sham OVX mice.
Plasma FSH levels in vehicle treated mice fluctuated, but
showed an overall trend toward an increase (Figure 2B). The
average level of FSH increased about 60% at 16.5 months of
age, but the increase was not statistically significant. Like plasma
Frontiers in Neurology | www.frontiersin.org

Brain Metals
The concentration of metals in the brains of 16.5 month
old mice in control, leuprolide, and 16 months old sham,
ovariectomized and ovariectomized + leuprolide groups is
shown in Figures 3A–H. Leuprolide acetate did not induce
a significant change in the concentrations of any metals
tested. There was however a trend toward a decrease in the
concentration of Cu (about 7%), Zn (about 5%), but these
changes were not statistically significant. Ovariectomy also did
not significantly alter brain metal ion concentrations although
there was a trend to a decrease with all metals, with the decrease
in brain Cu being most significant (P = 0.087). These decreases
were partly reversed by leuprolide acetate treatment for all metals,
but again were not statistically significant (Figure 3C). Since
leuprolide acetate decreases both plasma LH and FSH after 9
months of treatment (Figures 2A,B), the decrease in brain metals
may be due to either decreased LH receptor or FSH receptor
signaling, or increased GnRH receptor signaling. Since FSH
receptors have not been identified in the brain (data not shown),
it is unlikely that FSH is mediating changes in the concentrations
of these metal ion concentrations.
To further examine changes in plasma LH and FSH with
brain metal ion concentration, we performed a regression
analysis (Table 2). The concentrations of plasma LH and FSH
were highly positively correlated (r = 0.848, n = 29, P <
0.001), indicating that LH and FSH concentrations move in
concert with one another. The concentration of brain Cu
was significantly negatively correlated with LH (-0.370, n =
30, P < 0.05) and FSH (-0.422, n = 29, P < 0.05). No
other brain metals were correlated with LH or FSH. However,
the concentrations of Fe, Zn, Cu, Mn and Co in the brain
4
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FIGURE 1 | Changes in body weight with aging in ovariectomized and leuprolide acetate treated mice. (A) Female C57B6JL mice at the age of 7.5 months were
treated either with vehicle (saline) or leuprolide acetate (1.5 mg/kg) monthly for 9 months and body weights determined each month. (B) C57B6JL mice at the age of
7.0 months were sham operated or ovariectomized. Ovariectomized animals were either treated with vehicle (saline) or leuprolide acetate (1.5 mg/kg) monthly for 9
months and body weights determined each month. Results are presented as mean ± SEM, n = 6.

FIGURE 2 | Changes in plasma LH and FSH with aging in ovariectomized and leuprolide acetate treated mice. Female C57B6JL mice at the age of 7.5 months were
treated either with vehicle (saline) or leuprolide acetate (1.5 mg/kg) monthly, blood was taken at 0, 1, 3, 6, and 9 month and LH (A) and FSH (B) concentrations were
assayed via RIA. C57B6JL mice at the age of 7.0 months were sham operated or ovariectomized. Ovariectomized animals were either treated with vehicle (saline) or
leuprolide acetate (1.5 mg/kg) monthly for 9 months and blood samples collected at 0, 1, 3, and 9 month, and LH (B) and FSH (D) levels assayed via RIA. Results are
presented as mean ± SEM, n = 6, *p < 0.05.

Al, and Co with Mn. There was no correlation between body
weight and either plasma hormones or brain metals (data
not shown).

were all significantly positively correlated with one another
(P ≤ 0.01, n = 29/30). Other significant positive correlations
included Li with Fe, Cu, Mn and Co; Ni with Zn, Co and
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FIGURE 3 | Changes in brain metal ion concentrations with ovariectomy and leuprolide acetate treatment of mice. Mice as described in Figures 1, 2 were sacrificed
after 9 months of treatment, and their brains collected for metal analysis with ICP-MS. Samples were corrected for trace amounts of metals from buffer, and the
concentration of metal ion was normalized to total protein in the samples. (A) Fe, (B) Zn, (C) Cu, (D) Mn, (E) Co, (F) Ni, (G) Li, and (H) Al. Results are presented as
µg/mg or ng/mg protein; mean ± SEM, n = 6.

DISCUSSION

other mammals, where significant elevations in both LH and FSH
are observed following estropause/menopause (24, 38–41). These
results suggest that there was sufficient residual production by the
follicle depleted ovary, of sex steroids like estrogens and protein
hormones like the inhibins, in order to suppress elevations in
circulating LH/FSH that are observed in other species (42, 43).
In mice, ovariectomy should therefore not be equated with
estropause with respect to the interpretation of biochemical and

Circulating Sex Hormone Concentrations
Associated With Aging, Ovariectomy and
Lupron Treatment in Female Mice
We observed a non-significant increase in plasma LH and FSH
concentrations between 7.5 and 16.5 months of age in ovary
intact and Sham OVX female C57B6SJL mice. This is contrary to

Frontiers in Neurology | www.frontiersin.org
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TABLE 2 | Correlation analysis of plasma hormone and brain metal ion concentrations.
LH
LH
FSH

FSH

Fe

Zn

Cu

Mn

Ni

Al

Li

1
0.85***

1

Fe

−0.19

0.16

Zn

−0.23

−0.26

0.64***

1

Cu

−0.37*

−0.42*

0.62***

0.51**

1

Mn

−0.27

−0.28

0.88***

0.74***

0.68***

Co

−0.25

−0.20

0.62***

0.57**

0.74***

0.68***

Ni

−0.01

0.11

0.34

0.43*

0.17

0.24

Al

−0.01

0.12

−0.17

−0.28

−0.09

Li

−0.01

−0.13

*P

Co

1

0.55**

0.25
0.35

0.46**

1

0.47**

1
0.58***

1

0.06

0.66***

0.46*

0.17

1
−0.28

1

< 0.05; ** P < 0.01; *** P < 0.001.

and gonadotropins may regulate the weight gain observed with
ovariectomy/estropause (Figure 1A).

physiological endpoints resulting from these different forms of
HPG axis dysregulation. As in other species, leuprolide acetate
lowered blood gonadotropin concentrations in the aging intact
and ovariectomized female mouse [Figure 2; (44–46)].
Ovariectomy induced a gradual increase in plasma LH over
9 months between 7 and 16 months of age, while plasma FSH
levels increased dramatically within 1 month of ovariectomy and
remained elevated through to 16 months of age. The abrupt
increase in plasma FSH but gradual increase in plasma LH
following ovariectomy is consistence with previous findings in
ovariectomized mice (35, 36) and many other species including
sheep where LH and FSH are thought to be subjected to
differential regulation after ovariectomy (47). Alternatively, it
is possible that since blood was collected prior to the next
dose of leuprolide, that the previously injected leuprolide was
becoming ineffective at suppressing plasma LH/FSH. However,
this is difficult to reconcile with the fact that leuprolide treatment
decreased plasma LH and FSH in the ovariectomized animals
(Figure 2). Irrespective, these results indicate that the pituitary
is responding to the loss of sex steroid feedback, particularly
following ovariectomy, with the pituitary capable of producing
large quantities of gonadotropins. Overall, these results indicate
that ovariectomy is not equivalent to estropause with respect to
hormonal changes.

Hormonal-Induced Modulation of Brain
Metals
Our study demonstrates a possible negative relationship
between circulating gonadotropin concentrations and brain
Cu concentration (Figure 3 and Table 1). Ovariectomy, which
induces an increase in GnRH, LH and FSH secretion, but
a decrease in sex steroid secretion, correlated with a trend
toward an increase in brain Cu concentration, suggesting that
these hormonal changes either decrease neuronal Cu uptake
or increase neuronal Cu efflux. Interestingly, leuprolide acetate
treatment of ovariectomized mice prevented the ovariectomyinduced decline in brain Cu levels, suggesting that either LH,
FSH or GnRH receptor signaling may play an important role in
Cu homeostasis in the brain. Estrogen along with progestogen
has been shown to increase serum Cu, ceruloplasmin and brain
Cu levels in humans and rats, while the hepatic levels of Cu
decrease (48).
It is not clear if these hormonal changes redistribute metals
within the brain, or alter synaptic metal ion release. Both synaptic
Zn and Cu are released during normal synaptic transmission.
Zn, like glutamate, is released during paroxysmal activity (49–
51). Zn is released in a calcium-dependent manner from
the hippocampal mossy fiber terminals during spontaneous
activity (52), after stimulation evoked electrically (53) after
administration of K+ and after administration of kainic acid (51,
54). The physiological purpose of such high Zn concentrations
in the hippocampus is unclear but some workers have proposed
that this large trans-synaptic movement of Zn may have a
normal signaling function (49, 55) and be involved in longterm potentiation i.e., in the processing of memory formation
(56). Changes in behavior of multiple channels and receptors
(57, 58), in particular inhibition of NMDA receptors (59) have
been reported.
It has been shown that extracellular Cu modulates the
secretory function of peptidergic neurons and plays an important
modulatory role in the central nervous system. Cu is released
in a Ca-dependent manner from vesicles of peptidergic neurons

Hormonal Regulation of Body Weight
Although there was no difference between the weights of shamoperated, ovariectomized and ovariectomized plus leuprolide
treated animals at 15 months (8 months post-treatment;
Figure 1B), ovariectomized and ovariectomized plus leuprolide
treated mice reached significantly heavier weights earlier (9
months) than sham-operated mice (11 months), suggesting that
the loss of estrogens rather than the elevation in gonadotropins
was responsible for this faster weight gain. This is supported by
the more rapid gain in body weight by the sham OVX group
at 12.5 months of age that parallels the loss of reproductive
function (loss of circulating estradiol) at this time in female
mice. A similar increase in weight gain was observed for vehicle
treated and leuprolide acetate treated mice between 13.5 and 14.5
months of age suggesting that hormones other than sex steroids
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following K+ -induced depolarization of hypothalamic tissues
in vitro (60, 61). The release of Cu (bound to an intracellular
chelator) during depolarization is thought to oxidize thiols of
the gonadotropin-releasing hormone (GnRH) granule in an
oxygen dependent manner thereby altering the permeability of
granule membranes and mediating the release of GnRH and
α-melanotropin from hypothalamic granules of explants of the
median eminence area (MEA) (62–64). These alterations in
membrane permeability are specific for complexed Cu, and to
a lesser extend Zn (62, 63). Released Cu might also act to
complex GnRH, since injection of rats with Cu complexed GnRH
brings about a high release of LH and even higher release of
FSH compared with uncomplexed GnRH or metal ion alone
in ovariectomized, estradiol, and progesterone pretreated rats
(65). The Ni complex showed a similar although lesser effect.
Although the Zn complex had similar potency to free GnRH, it
had higher FSH-releasing ability (65). How the metal ion and
release of gonadotropins interplay with each other remains to
be determined.
Brain Fe concentrations trended lower following
ovariectomy while leuprolide partially restored decline brain Fe
concentrations, although these changes following our chronic
experimental manipulations were not significantly different
(Figure 3 and Table 1). Our results suggest that like Cu, either
LH or GnRH receptor signaling may play an important role
in Fe homeostasis in the brain. One previous study using an
immunohistochemical method of detection noted a modest
but significant increase in histochemically detectable Fe in the
cerebral cortex during proestrus, when serum estradiol and
gonadotropin levels are transiently upregulated (31). Serum
progesterone levels which peak during proestrus also might
explain the increase in histochemically detectable Fe in the
cerebral cortex at this time. There is evidence that the expression
of proteins involved in Fe metabolism fluctuate during the
oestrous cycle, 1) endothelial cells in chick brain express hen
oviduct transferrin receptor (66), which can bind transferrin,
ferritin and lactoferrin (67, 68). Expression of this receptor is
induced by estrogen (69), so its expression should be maximal
during proestrus, 2) lactoferrin protein and mRNA expression in
mouse genital tract are positively correlated with estradiol levels
(70) and lactoferrin gene expression is induced by estrogen in
the reproductive tracts of rats, hamsters and primates (71, 72).
Progesterone may antagonize the effects of estrogen, particularly
with respect to lactoferrin expression in the mouse reproductive
tract (73).
Like Cu and Fe, ovariectomy tended to induce a decrease while
leuprolide partially restored brain Zn levels, although again these
changes were not statistically significantly different (Figure 3
and Table 1). Our results suggest that like Cu and Fe, either
LH, or GnRH receptor signaling may play an important role
in Zn homeostasis in the brain. This result is in contrast to
those of Lee and colleagues, where ovariectomy of 5-month old
female mice slightly increased total and hippocampal synaptic
vesicle Zn levels, and estrogen replacement returned these Zn
concentrations to control levels (74). These changes appeared
to be mediated by estrogen-induced decreases in Zn transporter
3 (Znt3) expression and the delta subunit of ad aptor protein
complex (AP)-3, which modulates the level of Znt3 levels.
Frontiers in Neurology | www.frontiersin.org

Estrogen has been shown to elevate liver Zn levels (75). Since
both leuprolide treatment and estradiol treatment have the
effect of rebalancing the ratio of estrogens to gonadotropins,
the ratios of these hormones may be a better predictor of Zn
influx vs. Zn efflux in the brain compared to either hormone
concentration alone.
In the context of the preceding observations, our present data
support the possibility that fluxes in serum reproductive
hormones during the estrous cycle could influence the
intercellular transport of certain metals in the brain. In our
experiments, ovariectomy was performed 9 months prior to and
leuprolide administered for 9 months prior to collection of brain
tissue for metal ion analysis. Homeostatic mechanisms may have
compensated for changes in brain metals during these chronic
experimental manipulations. It will be interesting to determine
brain metal ion concentrations in a short-term study.

Metal Ion Agonism/Antagonism
A number of studies have demonstrated that certain metals move
in the same direction or in the opposite direction to one another.
For example, Zn and Cu are biologically antagonistic; alterations
in Zn metabolism directly impact Cu metabolism and vice versa
(76). In vitro studies also indicate the antagonistic relationship
of Zn and Cu; Aß binds equimolar amounts of Cu2+ and Zn2+
at pH 7.4, but Cu2+ displaces Zn2+ from Zn2+ :Aß complexes
under acidic conditions [pH 6.6; (77)]. In contrast to previous
literature, we observed a positive correlation between brain Cu
and Zn (Table 2; r = 0.51).
Zn and Fe antagonism (78) also has been demonstrated from
nutritional studies; Fe reduces the absorption of Zn across the
gut (79–82). The interdependence of Fe and Zn in the brain
also has been studied. In contrast to the gut, Fe and Zn appear
to have an agonistic relationship. Fe deficient rats administered
Fe + Zn have significantly higher numbers of Mossy fiber (NF)
cells than either metal ion treatment alone, suggesting that since
MF of the hippocampus are thought to be involved in LTP, this
agonistic relationship is important for neurotransmission (83).
We also noted a positive relationship between Fe and Zn (Table 2;
r = 0.64).

Neurological Implications of Hormonal
Induced Changes in Metal Ion
Homeostasis
Given the normal physiological functions of brain metals,
dysregulated metal ion homeostasis induced by hormonal,
nutritional or genetic factors could be very detrimental to neuron
health. Although gross changes in metals in a brain hemisphere
were relatively small in our study following dysregulation of
the HPG axis via ovariectomy and/or GnRH superagonist
treatment (Figure 3), previous studies noted above demonstrate
significant changes in metals between sex, following castration
and during the estrous cycle suggesting that hormone-induced
metal ion changes are important for normal neurotransmission
and other functions. One possible explanation for the small
global changes in metals in our study is that adaptive
changes in brain sex hormones may mask metal ion changes
induced by endocrine changes in sex hormones with aging
or following ovariectomy. Previous studies indicate regional
8
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differences in metals throughout the brain (see Introduction)
and association with AD neuropathology (84, 85). Interestingly,
regional changes in neurosteroids also have been reported
in response to stress (86), while hydrocortisone has been
reported to upregulate the expression of the potent metal ion
binder metallothionein in the choroid plexus of rats (87).
Thus, hormonal dysregulation of regional metal ion homeostasis
could have implications for inducing neuroinflammation, AD
neuropathology and neuroodegeneration (40, 88). Future studies
directed at determining whether endocrine hormones elicit
regional changes in metals and/or neurohormone concentrations
resulting in neurodegeneration, are warranted.
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